WESTMINSTER, CA--(Marketwired - Sep 19, 2016) - BioLargo, Inc. (OTCQB: BLGO) announced it had closed its 2015
Unit Offering to further investments. The company also reported that with the closing of this offering and the clearing of
remaining funds, its cash balance will be just over $2,100,000.
Additionally, the company announced that it had converted $250,000 of outstanding debt owing under the terms of a $300,000
secured line of credit into mandatorily convertible debt and warrant structure on terms substantially equivalent to the company's
2015 Unit Offering.
Dennis P. Calvert, President and CEO of BioLargo, stated, "We are thankful for the support by our shareholders and investors
as we advance our technology and commercial efforts. Our AOS Filter System continues to garner attention from an expanding
audience of industry, public funding sources, and potential strategic partners. Since our technical symposium approximately one
month ago, we are experiencing a swell of attention and interest in anticipation of our first commercial pilots planned in early
2017. We are also busy advancing the automation and optimization of the system as it moves from alpha to beta in preparation of
its first commercial pilots, as well as developing more operations oriented staff. Sales from our Odor-No-More subsidiary
continue to improve as we build out infrastructure to support an increased focus on sales, marketing and manufacturing. We are
also working closely with new distributors and agents to expand sales of our CupriDyne Clean (www.cupridyne.com) industrial odor control product. At this time, our advanced wound care
products in development remain on target for 510(k) application with the FDA in early 2017. This is a great time at BioLargo and
our future is bright!"
The company reported the above information on Form 8-K (link here).
About BioLargo, Inc.
BioLargo, Inc. (OTCQB: BLGO) makes life better by delivering sustainable technology-based products that help solve some of the
most widespread problems threatening the world's supply of water, food, agriculture, healthcare and energy. More information can
be found about the company and its subsidiaries at www.BioLargo.com. Its
subsidiary BioLargo Water, Inc. (www.BioLargoWater.com) showcases the
Advanced Oxidation Systems, including its AOS Filter System -- a product in development specifically designed to eliminate
common, troublesome, and dangerous (toxic) contaminants in water in a fraction of the time and cost of current technologies. It
is the winner of the Technology Star award by New Technology Magazine for its breakthrough innovation for the oil
industry and is named the Technology Innovation Leader in the water treatment market by Frost & Sullivan. BioLargo also owns a
50% interest in the Isan System, which was honored with a "Top 50 Water Company for the 21st Century" award by the Artemis
Project now being commercialized under a license to Clarion Water, Inc. BioLargo's subsidiary Odor-No-More Inc., features
award-winning products serving the pet, equine, military supply and consumer markets, including the Nature's Best Solution® and
Deodorall® brands (www.OdorNoMore.com). BioLargo's subsidiary Clyra
Medical Technologies, Inc. (www.ClyraMedical.com) focuses on advanced
wound care management.
Safe Harbor Statement
The statements contained herein, which are not historical, are forward-looking statements that are subject to risks and
uncertainties that could cause actual results to differ materially from those expressed in the forward-looking statements,
including, but not limited to, the risks and uncertainties included in BioLargo's current and future filings with the Securities
and Exchange Commission, including those set forth in BioLargo's Annual Report on Form 10-K.